Note 4 - Acquisitions (Details Textual)

Note 4 - Acquisitions (Details Textual) - USD ($) $ in Thousands			5 Months Ended	6 Months Ended
	Aug. 01, 2018	Jul. 02, 2018	Dec. 31, 2018	Dec. 31, 2018	Dec. 31, 2018	Dec. 31, 2018	Dec. 31, 2017
Payments to Acquire Businesses, Net of Cash Acquired, Total				$ 272,287			$ 10,644
QT Holdings Corporation [Member]
Payments to Acquire Businesses, Net of Cash Acquired, Total		$ 20,404				$ 20,461
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High		$ 51,000	$ 51,000	51,000	$ 51,000	51,000
Goodwill, Purchase Accounting Adjustments					3,764
QT Holdings Corporation [Member] \| Developed Technology Rights [Member]
Finite-Lived Intangible Asset, Useful Life		15 years
Exosome Diagnostics, Inc [Member]
Payments to Acquire Businesses, Net of Cash Acquired, Total	$ 251,825		251,825
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	325,000		325,000	$ 325,000	$ 325,000	$ 325,000
Goodwill, Purchase Accounting Adjustments			$ 2,435
Business Acquisition, Goodwill, Expected Tax Deductible Amount	0
Exosome Diagnostics, Inc [Member] \| Calendar Year 2020 EBITA Between $45 Million and $58 Million or Greater [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	250,000
Exosome Diagnostics, Inc [Member] \| Calendar Year 2022 EBITA for A New Instrument Product Between $54 Million and $70 Million or Greater [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	45,000
Exosome Diagnostics, Inc [Member] \| Calendar Year 2022 EBITA for Remaining Business Between $150 Million and $190 Million or Greater [Member]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	$ 30,000
Exosome Diagnostics, Inc [Member] \| Developed Technology Rights [Member]
Finite-Lived Intangible Asset, Useful Life	15 years

Quarterly report pursuant to Section 13 or 15(d)

Note 4 - Acquisitions (Details Textual)